Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-molecular-weight heparin sodium gel plus oral isotretinoin for moderate to severe acne
ChiCTR2400090222Phase 4Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of low molecular weight heparin calcium and isotretinoin in acne vulgaris (2 arms), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Percentage change in total skin lesion count from baseline at week 24. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
low molecular weight heparin calciumisotretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on ChiCTR2400090222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090222.